Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15183485 | 0.83 | MAOB (0.44) | MAOBDAOSLC2A1KDM1ASIGMAR1 | |
| SCHEMBL12563445 | 0.82 | SIGMAR1 (0.40) | MAOBDAOKDM1ASIGMAR1 | |
| SCHEMBL25795138 | 0.79 | SMN1; SMN2 (0.43) | SIGMAR1 | |
| SCHEMBL10226087 | 0.78 | MAOB (0.46) | MAOBDAOSLC2A1KDM1ASIGMAR1 | |
| SCHEMBL18501576 | 0.78 | SIGMAR1 (0.36) | MAOBDAOKDM1ASIGMAR1 | |
| SCHEMBL15183488 | 0.77 | CHRM4 (0.35) | — | |
| SCHEMBL15383395 | 0.76 | MAOB (0.48) | MAOBDAOSLC2A1KDM1ASIGMAR1 | |
| SCHEMBL17524004 | 0.76 | MAOB (0.48) | MAOBDAOSLC2A1KDM1ASIGMAR1 | |
| SCHEMBL21016400 | 0.76 | CHRM4 (0.31) | — | |
| SCHEMBL20805325 | 0.76 | MAOB (0.48) | MAOBDAOSLC2A1KDM1ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | MAOB 3638/4885DAO 4176/4885SLC2A1 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.